For people with heart disease but not diabetes, taking semaglutide seems to lower the chance of having a non-fatal heart attack over about three years — 2.7% of users had one versus 3.7% who didn’t...

In adults over 45 with heart disease and obesity but no diabetes, a weekly injection of semaglutide at 2.4 mg for about 3.3 years lowers the combined risk of heart-related death, heart attack, or stroke compared to a placebo.

If you're 45 or older, have heart disease, and are overweight but don’t have diabetes, taking semaglutide for about 3 years might lower your chance of having a serious heart problem by a small amount — about 1.5%. That means 67 people need to take it for one person to avoid a heart event, which gives a clearer picture than the often-shared 20% drop in risk.

Among adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with a 29% lower risk of dying from cardiovascular causes compared to taking a placebo over approximately 3.4 years.

In adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with an 18% lower risk of major cardiovascular events compared to a placebo over approximately 3.4 years.

In obese adults with existing heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg is associated with a lower rate of serious heart-related events such as heart attack or stroke.